No Data
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○List of stocks that have shifted to Buy market Code Stock Name Closing Price SAR Tokyo Main Board <1719> Ando Hazama 1189 1164 <1861> Kumagai Gumi 39903865 <1873> Japan House HD 329317 <1884> Nihon Doro 17801726 <1975> Asahi Kogyo 22882219 <2154> Open UP 17941729 <2175> SMS 15651520 <2264> Morinaga
Capricor Therapeutics Submits BLA for Deramiocel, Potentially First Therapy for DMD Cardiomyopathy, Triggering $10 Million Milestone Payment From Nippon Shinyaku
Stocks that moved the previous day part 1 Market Overview E, Migaro HD, KADOKAWA etc.
Stock name <code> Closing price on the 23rd ⇒ Change from previous day Satsudora Holdings <3544> 839 +53 The operating profit for the first half of the year increased by 28.7%, expanding from a 1.4% increase in the first quarter. Yoshimura Food <2884> 1368 +74 Reports indicate that the Chinese government is considering the resumption of imports of Aquatic Products from Japan. Mitsubishi Motors <7211> 491.1 +24.5 Reports suggest that the new holding companies for Honda <7267> and Nissan <7201> are considering establishing by August 2026.
The Nikkei Average rebounded for the first time in seven days, as buying prevailed due to the avoidance of a U.S. government agency shutdown.
Last weekend, the USA market's Dow Inc average closed up by 498.02 points at 42840.26 points, and the Nasdaq closed up by 199.83 points at 19572.60 points. While some tech stocks saw early selling, leading to a decline at the open, the November Personal Consumption Expenditures (PCE) price index suggested progress in inflation control, supporting an increase. The Dow Inc average briefly surged over 800 points higher compared to the previous day, but faced expiration of stock index Futures and Single Options for individual stocks.
GFA, Ise Chemical, Hokushin, etc.
A rebound after a turnaround. The second quarter financial results were announced last weekend, with an operating profit of 19.7 billion yen for the September to November period, a decrease of 0.7% compared to the same period last year, significantly slowing down from the 20.2% increase in the first quarter.
Nichirin Pharmaceutical and others continue to be ranked, viewing the lawsuit results with Sarepta in the USA negatively.
Nisshin Pharma <4516> has ranked in (as of 1:32 PM). It has significantly fallen. The verdict results of the lawsuit in the USA with Sarepta Therapeutics have been announced, and it is viewed negatively. In the trial held in the Delaware District Court, it seems the jury ruled that the patent obtained by Sarepta Therapeutics from the University of Western Australia is valid, the damages amounting to 115.2 million dollars, and that Nisshin Pharma's patent is invalid. Volume change rate ranking top [As of December 23, 1:32 PM.
No Data